A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses

Hepatitis virus infections caused by HBV, HCV, HDV, and HEV represent a global health threat. Treatment options remain limited, notably due to the lack of knowledge about molecular virus-host interactions. Moreover, the interplay between these four viruses in the context of co-infections remains unknown. In this study, we report the first <i>in vitro</i> system that allows for mono and multi-infections with these four viruses and characterize the broad antiviral activity of farnesoid X receptor agonists, paving the way for the development of new strategies for viral cure.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-02-28
DOI
https://doi.org/10.1016/j.jhepr.2025.101383
Citations
3
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
4.06

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses

Anna Salvetti, Guillaume Passot, Éloi R. Verrier, Raphaël Darteil et al.
3 citations
JHEP Reports
Hepatitis B Virus Studies
4.06
article

A novel in vitro system for simultaneous infections with hepatitis B, C, D and E viruses

Anna Salvetti, Guillaume Passot, Éloi R. Verrier, Raphaël Darteil, Michel Rivoire, Caroline Pons, Philip Meuleman, Eike Steinmann, Olivier Diaz, Amse De Meyer, Virginie Doceul, Nicole Pavio, Maud Michelet, David Durantel, Romain Barnault, Heiner H. Wedemeyer, Lieven Verhoye, Julie Lucifora, Roxanne Fouillé
article en
3 citations

Abstract

Hepatitis virus infections caused by HBV, HCV, HDV, and HEV represent a global health threat. Treatment options remain limited, notably due to the lack of knowledge about molecular virus-host interactions. Moreover, the interplay between these four viruses in the context of co-infections remains unknown. In this study, we report the first <i>in vitro</i> system that allows for mono and multi-infections with these four viruses and characterize the broad antiviral activity of farnesoid X receptor agonists, paving the way for the development of new strategies for viral cure.

JHEP ReportsVol. 7(5)
Université Claude Bernard Lyon 1 (FR), École Normale Supérieure de Lyon (FR), Centre National de la Recherche Scientifique (FR), Inserm (FR), École Nationale Vétérinaire d'Alfort (FR), Ghent University (BE), Medizinische Hochschule Hannover (DE), Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR), Hospices Civils de Lyon (FR), Centre Léon Bérard (FR), German Center for Infection Research (DE), Centre de Recherche en Cancérologie de Lyon (FR), Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR), Centre International de Recherche en Infectiologie (FR), Institute for Translational Medicine and Liver Disease (FR), Université de Strasbourg (FR), Ruhr University Bochum (DE)
Deutsches Zentrum für Infektionsforschung, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Österreichischen Akademie der Wissenschaften, Fonds Wetenschappelijk Onderzoek, Université de Strasbourg, Universiteit Gent, Centre National de la Recherche Scientifique, Vlaamse regering, CHIST-ERA
Good health and well-being
Openalex Percentile: Top 7%
Hepatitis B Virus Studies
4.06
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.